Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Renal method: Renal impairment categories as defined by the cited product label Source date: DailyMed SPL version 43, posted Oct 28, 2026 Retrieved: 2026-11-07
Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.
Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter. Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
